Open AccessAdjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
Author(s) -
ChunJen Liu,
J. R. Chang,
PoHuang Lee,
Lin Deng,
Cheng Chung Wu,
Long Bin Jeng,
Yih Jyh Lin,
King Tong Mok,
Wei Chen Lee,
Hong Zen Yeh,
Ming-Chih Ho,
Shih-Chieh Yang,
Mei Yang,
Ming Yu,
ReyHeng Hu,
Cheng Yuan Peng,
Kuan Lang Lai,
ShuWen Chang,
PeiJer Chen
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i32.11384
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , adjuvant , adjuvant therapy , hepatitis b , oncology , surgery , cancer
To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection.